A Global Pharmaceutical Company
A Global Pharmaceutical Company
A Global Pharmaceutical Company
| API's | Category | Specifications | Regulatory Status |
|---|---|---|---|
|
Atenolol |
Anti-Hypertensive |
IP/BP/EP/USP |
CEP, EU GMP, USDMF |
|
Amlodipine Besylate |
Anti-Hypertensive |
IP/BP/EP/USP |
DMF Available |
|
Metoprolol Succinate |
Anti-Hypertensive |
IP/BP/EP/USP |
DMF Available, USDMF filed |
|
Metoprolol Tartrate |
Anti-Hypertensive |
IP/BP/EP/USP |
DMF Available, USDMF filed |
|
Roxithromycin |
Macrolides |
IP/BP/EP |
CEP, KFDA |
|
Azithromycin |
Macrolides |
IP/BP/EP/USP |
CEP, USDMF filed |
|
Clarithromycin Granules 27.5% |
Macrolides |
In-House |
DMF Available |
|
Clarithromycin Granules 33% |
Macrolides |
In-House |
|
|
Clarithromycin Granules 43% |
Macrolides |
In-House |
DMF Available |
|
Pregabalin |
Neuromodulator |
IP/EP/In-House |
CEP, USDMF filed |
|
Ceftriaxone Sodium |
Sterile Cephalosporins |
IP/BP/EP/USP |
DMF Available |
|
Cefotaxime Sodium |
Sterile Cephalosporins |
IP/BP/EP/USP |
DMF Available |
|
Cefepime (with L-Arginine) for Injection |
Sterile Cephalosporins |
IP/USP |
|
|
Meropenem (with Sodium Carbonate) for Injection |
Carbapenems |
IP/USP |
DMF Available |
|
Doripenem |
Carbapenems |
In-House |
DMF Available |
|
Biapenem |
Carbapenems |
In-House |
DMF Available |
|
Lymecycline |
Anti-Acne, Anti-Infective |
EP |
DMF Available, CEP filed |
|
Nitroxoline |
Antibiotic |
In-House |
DMF Available |
|
Ticagrelor |
Anti-Thrombotic |
IP / EP/ USP/ In-House |
DMF under preparation |
|
Rivaroxaban |
Anti-Thrombotic |
IP / EP/ USP/ In-House |
DMF under preparation |
|
Apixaban |
Anti-Thrombotic |
In-House |
DMF under preparation |
|
Empagliflozin |
Anti-Diabetic |
In-House |
DMF under preparation |
|
Dapagliflozin Propanediol Monohydrate |
Anti-Diabetic |
In-House |
DMF under preparation |
|
Faropenem |
Carbapenems |
JP/In-House |
DMF under preparation |
|
Tebipenem |
Carbapenems |
In-House |
DMF under preparation |
| Pellets | Category |
|---|---|
|
Duloxetine Pellets 17%, 21.5% |
Anti-Depressent |
|
Venlafaxine Pellets 33% |
Anti-Depressent |
|
Dexlansoprazole Pellets 20%, 23% |
Proton Pump Inhibitor |
| API's | Category | R&D Sample availability | R&D Tech pack availability | Specifications |
|---|---|---|---|---|
|
Canagliflozin Hemihydrate |
Anti-Diabetic |
Available |
Available |
In-House |
|
Ertapenem |
Carbapenems |
Available |
Available |
In-House |
|
Imipenem |
Carbapenems |
Nov 2022 |
Dec 2022 |
In-House |
|
Montelukast Sodium |
Anti-asthmatics |
Available |
Under Lab Development |
IP/EP/USP |
|
Ketoconazole |
Anti-fungal |
Oct 2022 |
Under Lab Development |
IP/EP/USP |
|
Clopidogrel Bisulphate |
Cardiovascular |
Nov 2022 |
Under Lab Development |
IP/EP/USP |
|
Nitrofurantoin Monohydrate |
To treat urinary tract infection |
Nov 2022 |
Under Lab Development |
IP/EP/USP |
|
Nitrofurantoin Anhydrous |
To treat urinary tract infection |
Nov 2022 |
Under Lab Development |
IP/EP/USP |
|
Nitrofurantoin Macro crystal |
To treat urinary tract infection |
Nov 2022 |
Under Lab Development |
IP/EP/USP |
|
Rosuvastatin calcium |
Lipid-Lowering Agents |
Available |
Under Lab Development |
IP/EP/USP |
|
Lacosamide |
Anticonvulsants |
Nov 2022 |
Under Lab Development |
EP/USP |
|
Buspirone Hydrochloride |
Antianxiety Agents |
Jan 2023 |
Under Lab Development |
IP/EP/USP |
|
Macitentan |
To treat pulmonary arterial hypertension |
Feb 2023 |
Under Lab Development |
In-House |
|
Riociguat |
To treat pulmonary hypertension |
Mar 2023 |
Under Lab Development |
EP/USP |
|
Edoxaban Tosylate |
Anticoagulant |
Oct 2022 |
Under Lab Development |
In-House |
|
Ertugliflozin L-pyroglutamic Acid |
Anti-Diabetic |
Mar 2023 |
Under Lab Development |
In-House |
|
Hypromellose Acetate Succinate (HPMCAS) |
Excipient/ Coating material |
Jun 2024 |
Aug 2024 |
USP / EP |
For more information on APIs, send an e-mail to: api@kopran.com